- Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002; 82(2): 331–71.
- Creutz CE, et al. Protection of the Membrane Permeability Barrier by Annexins. Biochemistry 2012; 51(50): 9966–83.
- Draeger A, et al. Plasma membrane repair and cellular damage control: the annexin survival kit. Biochem Pharmacol 2011; 81(6): 703–12.
- Sadoudi S, et al. AN IMBALANCE BETWEEN PLASMA ANNEXIN-A5 AND PHOSPHATIDYLSERINE EXPRESSION IN ERYTHROCYTES PROMOTES VASCULAR INJURY DURING SICKLE CELL DISEASE. Haematologica 2016; 101: 295–6.
- van Tits L, et al. Ratio of plasma oxidized low-density lipoprotein and annexin A5 positively relates to severity of cardiovascular disease. Atherosclerosis Supplements 2007; 8(1): 85.
- Rand JH, et al. Reduction of circulating annexin A5 Levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol 2006; 194(1): 182–8.
- Roldan V, et al. Prognostic value of annexin A5-1 C/T polymorphism in a long term follow-up after premature myocardial infarction. Journal of Thrombosis and Haemostasis 2007; 5(4): 862–3.
- Roldan V, et al. [Annexin V levels in survivors of early myocardial infarction]. Rev Esp Cardiol 2002; 55(12): 1230–4.
- Klement K, et al. Accumulation of annexin A5 at the nuclear envelope is a biomarker of cellular aging. Mechanisms of Ageing and Development 2012; 133(7): 508–22.
- Ewing MM, et al. Annexin A5 prevents post-interventional accelerated atherosclerosis development in a dose-dependent fashion in mice. Atherosclerosis 2012; 221(2): 333–40.
- Ewing MM, et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol 2011; 31(1): 95–101.
- Gu CP, et al. Recombinant Human Annexin A5 Can Repair the Disrupted
Cardiomyocyte Adherens Junctions in Endotoxemia. Shock 2015; 44(1): 83–9. - Liu AQ, et al. Induction of Dendritic Cell-Mediated T-Cell Activation by Modified but Not Native Low-Density Lipoprotein in Humans and Inhibition by Annexin A5 Involvement of Heat Shock Proteins. Arteriosclerosis Thrombosis and Vascular Biology 2015; 35(1): 197–205.
- Burgmaier M, et al. AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(-/-) mice. Journal of Cellular and Molecular Medicine 2014; 18(10): 2117–24.
- Park JH, et al. Annexin A5 Increases Survival in Murine Sepsis Model by Inhibiting HMGB1-Mediated Proinflammation and Coagulation. Molecular Medicine 2016; 22: 424–36.
- Arnold P, et al. Recombinant Human Annexin A5 Inhibits Proinflammatory Response and Improves Cardiac Function and Survival in Mice With Endotoxemia. Critical Care Medicine 2014; 42(1): E32–E41.
- Kietselaer BL, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004; 350(14): 1472–3.
- Kenis H, et al. Annexin A5 Uptake in Ischemic Myocardium: Demonstration of Reversible Phosphatidylserine Externalization and Feasibility of Radionuclide Imaging. Journal of Nuclear Medicine 2010; 51(2): 259–67.
- Laufer EM, et al. Annexin A5: an imaging biomarker of cardiovascular risk. Basic Research in Cardiology 2008; 103(2): 95–104.
- Boersma HH, et al. Past, present, and future of annexin A5: From protein discovery to clinical applications. Journal of Nuclear Medicine 2005; 46(12): 2035–50.
- Miyagi A, et al. High-speed atomic force microscopy shows that annexin V stabilizes membranes on the second timescale. Nature Nanotechnology 2016; 11(9): 783–90.
- Oling F, et al. Trimers, dimers of trimers, and trimers of trimers are common building blocks of annexin A5 two-dimensional crystals. Journal of Structural Biology 2001; 133(1): 55–63.
- Bouter A, et al. Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair. Nature Communications 2011; 2.
- Insights LEKE. Raising Orphans: How Pharma Can Capture Value while Treating Rare Diseases. L.E.K. Consulting; 2014.
- Townsend N, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37(42): 3232–45.
- Mozaffarian D, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016; 133(4): e38–360.
- Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011; 10(5): 365–76.
- Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013; 339(6116): 166–72.
- Bouter A, et al. Review: Annexin-A5 and cell membrane repair. Placenta 2015; 36: S43–S9.
- Rand JH, et al. Antiphospholipid antibodies promote coagulation by disrupting the crystal structure of the annexin A5 anticoagulant shield over
- Gonzalez-Conejero R, et al. A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood 2002; 100(6): 2081–6.
- Cederholm A, et al. Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25(1): 198–203.
- Wan M, et al. Oxidized but not native cardiolipin has pro-inflammatory effects, which are inhibited by Annexin A5. Atherosclerosis 2014; 235(2): 592–8.
- Domeij H, et al. Annexin A5 inhibits atherogenic and pro-inflammatory effects of lysophosphatidylcholine. Prostaglandins & Other Lipid Mediators 2013; 106: 72–8.
- Wautier MP, et al. Red blood cell phosphatidylserine exposure is responsible for increased erythrocyte adhesion to endothelium in central retinal vein occlusion. J Thromb Haemost 2011; 9(5): 1049–55.
- Camus SM, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood 2015; 125(24): 3805–14.
- Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease. 2015. PR
- Liu AQ, et al. Induction of Dendritic Cell-Mediated T Cell Activation by Ldlx and Inhibition by Annexin A5. Journal of Atherosclerosis and Thrombosis 2014; 21: S31–S.
- Shelley S. The business of orphan drugs is booming Aug 2015 2015.
- Kenis H, et al. Annexin A5: Shifting from a diagnostic towards a therapeutic realm. Cellular and Molecular Life Sciences 2007; 64(22): 2859–62.
- Carmeille R, et al. Annexin-A5 promotes membrane resealing in human trophoblasts. Biochimica Et Biophysica Acta-Molecular Cell Research 2015; 1853(9): 2033–44.
- Carmeille R, et al. Membrane repair of human skeletal muscle cells requires Annexin-A5. Biochimica Et Biophysica Acta-Molecular Cell Research 2016; 1863(9): 2267–79.
- Friedman KA, et al. A Potential Role of Annexin A5 in Inflammatory Bowel Disease. Modern Pathology 2013; 26: 149A–50A.
- Schutters K. Annexin A5: Shifting from molecular imaging to therapeutic agent in cardiovascular diseases. Maastricht, Holland: University of Maastricht; 2013.
- Cederholm A, Frostegard J. Annexin A5 in cardiovascular disease and systemic lupus erythematosus. Immunobiology 2005; 210(10): 761–8.
- Camus SM, et al. Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease. Blood 2012; 120(25): 5050–8.
- Leader B, et al. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7(1): 21–39.
- Belhocine TZ, et al. Tc-99m-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. European Journal of Nuclear Medicine and Molecular Imaging 2015; 42(13): 2083–97.
- van Tits LJ, et al. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochemical and Biophysical Research Communications 2009; 390(1): 161–4.
- Bedrood S, et al. Annexin A5 Directly Interacts with Amyloidogenic Proteins and Reduces Their Toxicity. Biochemistry 2009; 48(44): 10568–76.
- Bianconi E, et al. An estimation of the number of cells in the human body. Ann Hum Biol 2013; 40(6): 463–71.
- Cederholm A, Von Landenberg P, Frostegard J. Decreased annexin A5 binding to endothelium is associated with cardiovascular disease in systemic lupus erythematosus and inhibited by IVIG. Atherosclerosis Supplements 2006; 7(3).
- Tzima E, et al. Annexin V relocates to the periphery of activated platelets following thrombin activation: an ultrastructural immunohistochemical approach. Cell Biol Int 1999; 23(9): 629–35.
- D’Arceuil H, et al. 99mTc annexin V imaging of neonatal hypoxic brain injury. Stroke 2000; 31(11): 2692–700.
- Narula J, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001; 7(12): 1347–52.
- Belhocine TZ, , et al. (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. Eur J Nucl Med Mol Imaging 2015; 42(13): 2083–97.
- Kusters DHM, et al. Molecular Imaging to Identify the Vulnerable Plaque-From Basic Research to Clinical Practice. Molecular Imaging and Biology 2012; 14(5): 523–33.
- Chen HH, et al. Cytoprotective nanoparticles by conjugation of a polyhis tagged annexin V to a nanoparticle drug. Nanoscale 2015; 7(6): 2255–9.
- CEBR. The economic cost of cardiovascular disease from 2014–2020 in six European economies, 2014.
- Research G. Global Cardiovascular Disease Market to 2022-Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth, 2016.
- Global Industry Analysis I. Peripheral Arterial Disease (PAD), 2012.
- Rogers S, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117(2): 313–9 e1.
- Läkemedelsförmånsverket TT-o. Lucentis (ranibizumab) hälsoekonomiskt kunskapsunderlag, 2012.
- CANACCORDGenuity, Report 2014.
- Research GV. Report, 2016.
- CDC. Ebola Outbreak in West Africa-Reported Cases Graphs, 2016.